Vancouver, BC, Canada - July 4, 2012, Vancouver, BC, Canada - Cardiome Pharma Corp., a research-based biopharmaceutical company, announced that chief executive officer Douglas G. Janzen has left the company, effective immediately.
Article continues below
Mr. Janzen served as Chief Financial Officer of Cardiome Pharma Corp. from January 6, 2003 to June 2006, Chief Business Officer since March 8, 2006 and Principal Accounting Officer until June 2006. From 2001 to 2002, Mr. Janzen served as Managing Director of Health Sciences and Partner of Cormark Securities Inc. (AKA:Sprott Securities Inc). He served as Equity Analyst of Loewen Ondaatje McCutcheon Limited, Research Division.
Prior to that, Mr. Janzen spent three years in corporate banking with Loewen Ondaatie McCutcheon Limited. Prior to Sprott Securities Inc., Mr. Janzen was the Head of Research and a Senior Health Sciences Analyst at Loewen, Ondaatje, McCutcheon Limited. He has been a Director of Medical Ventures Corp. since June 9, 2005.
Mr. Janzen has been an Independent Director of Neovasc Inc. since June 2, 2005, iCo Therapeutics Inc. since March 2, 2012 and Cardiome Pharma Corp. since January 6, 2003. He serves as Director of Sentinelle Medical, Inc., and BIOTECanada. He served as a Director of Bradmer Pharmaceuticals Inc. from February 2006 to August 2007.
Mr. Janzen received a Physiology Degree from the University of Saskatchewan and a Master's Degree in Biochemistry from the University of British Columbia.
William Hunter, a member of the Company’s board of directors, has been appointed interim CEO.
Dr. Hunter serves on Cardiome’s Board of Directors as Chair of the Nomination Committee, member of the Compensation Committee, and member of the Corporate Governance Committee. Dr. Hunter is one of Angiotech Pharmaceuticals Inc.’s, or Angiotech, co-founders and currently serves as President and Chief Executive Officer of Angiotech.
Active in a variety of business and scientific organizations, Dr. Hunter serves as the chair of the board for Neuromed Pharmaceuticals Ltd. Dr. Hunter is also an advisory board member for the Biotechnology MBA Program at the University of Western Ontario’s Ivey School of Business.
Dr. Hunter has been honoured with many awards including the 2006 Principal Award for Innovation from the Manning Foundation, the 2005 BC Innovation Council’s Cecil Green Award for Science and Technology Entrepreneurship and the co-recipient of 2006 NSERC Synergy Awards for Innovation along with Dr. Helen Burt, recognizing the collaboration between the University of British Columbia and Angiotech. ■